| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Atrial Fibrillation | 43 | 2024 | 403 | 12.690 |
Why?
|
| Heart Failure | 19 | 2025 | 247 | 7.770 |
Why?
|
| Vagus Nerve Stimulation | 16 | 2025 | 75 | 6.570 |
Why?
|
| Catheter Ablation | 12 | 2024 | 221 | 4.830 |
Why?
|
| Stroke Volume | 13 | 2025 | 123 | 4.320 |
Why?
|
| Electrocardiography | 21 | 2024 | 394 | 3.660 |
Why?
|
| Arrhythmias, Cardiac | 8 | 2024 | 163 | 3.290 |
Why?
|
| Heart Rate | 14 | 2024 | 379 | 3.250 |
Why?
|
| Autonomic Nervous System | 10 | 2025 | 112 | 3.180 |
Why?
|
| Ventricular Function, Left | 10 | 2025 | 112 | 2.880 |
Why?
|
| Microfluidic Analytical Techniques | 10 | 2024 | 18 | 2.810 |
Why?
|
| Microfluidics | 11 | 2025 | 13 | 2.750 |
Why?
|
| Anti-Arrhythmia Agents | 7 | 2024 | 117 | 2.610 |
Why?
|
| Myocardium | 4 | 2025 | 192 | 2.220 |
Why?
|
| Humans | 102 | 2025 | 28155 | 2.210 |
Why?
|
| Vagus Nerve | 7 | 2020 | 105 | 2.150 |
Why?
|
| High-Throughput Screening Assays | 6 | 2025 | 38 | 2.000 |
Why?
|
| Transcutaneous Electric Nerve Stimulation | 5 | 2021 | 25 | 1.870 |
Why?
|
| Myocardial Infarction | 7 | 2023 | 346 | 1.810 |
Why?
|
| Cardiac Resynchronization Therapy | 5 | 2021 | 18 | 1.740 |
Why?
|
| Male | 51 | 2025 | 13505 | 1.740 |
Why?
|
| Treatment Outcome | 26 | 2023 | 2383 | 1.730 |
Why?
|
| Randomized Controlled Trials as Topic | 7 | 2024 | 386 | 1.680 |
Why?
|
| Heart Atria | 8 | 2021 | 176 | 1.620 |
Why?
|
| Middle Aged | 36 | 2025 | 7164 | 1.510 |
Why?
|
| Death, Sudden, Cardiac | 4 | 2019 | 28 | 1.490 |
Why?
|
| Heart | 6 | 2025 | 223 | 1.460 |
Why?
|
| Female | 44 | 2025 | 15183 | 1.440 |
Why?
|
| Flow Cytometry | 6 | 2024 | 288 | 1.430 |
Why?
|
| Defibrillators, Implantable | 5 | 2019 | 45 | 1.420 |
Why?
|
| Aged | 28 | 2024 | 5416 | 1.330 |
Why?
|
| Quality of Life | 3 | 2024 | 491 | 1.300 |
Why?
|
| Obesity | 5 | 2024 | 668 | 1.290 |
Why?
|
| Stroke | 7 | 2023 | 252 | 1.190 |
Why?
|
| Inflammation | 4 | 2022 | 633 | 1.180 |
Why?
|
| Directed Molecular Evolution | 3 | 2025 | 7 | 1.110 |
Why?
|
| Primary Prevention | 3 | 2019 | 25 | 1.040 |
Why?
|
| Animals | 30 | 2025 | 10415 | 1.030 |
Why?
|
| Accessory Atrioventricular Bundle | 2 | 2018 | 17 | 1.020 |
Why?
|
| Risk Assessment | 7 | 2019 | 611 | 0.980 |
Why?
|
| Atrioventricular Node | 2 | 2018 | 69 | 0.970 |
Why?
|
| Cardiovascular Diseases | 4 | 2025 | 367 | 0.960 |
Why?
|
| Macrophages | 2 | 2025 | 296 | 0.950 |
Why?
|
| Ventricular Dysfunction, Left | 4 | 2020 | 64 | 0.950 |
Why?
|
| Heart Ventricles | 3 | 2025 | 137 | 0.950 |
Why?
|
| Rats, Inbred Dahl | 5 | 2024 | 16 | 0.930 |
Why?
|
| Cytokines | 4 | 2022 | 446 | 0.890 |
Why?
|
| Risk Factors | 16 | 2023 | 2087 | 0.890 |
Why?
|
| Biomarkers | 4 | 2024 | 763 | 0.880 |
Why?
|
| Heart Defects, Congenital | 2 | 2023 | 93 | 0.850 |
Why?
|
| Incidence | 8 | 2023 | 562 | 0.850 |
Why?
|
| Ganglia, Autonomic | 2 | 2022 | 55 | 0.850 |
Why?
|
| Observational Studies as Topic | 3 | 2023 | 54 | 0.850 |
Why?
|
| Autoantibodies | 5 | 2025 | 474 | 0.840 |
Why?
|
| Syndactyly | 1 | 2023 | 2 | 0.840 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2024 | 63 | 0.840 |
Why?
|
| Weight Loss | 1 | 2024 | 81 | 0.840 |
Why?
|
| Long QT Syndrome | 1 | 2023 | 13 | 0.830 |
Why?
|
| Frailty | 1 | 2023 | 19 | 0.820 |
Why?
|
| Echocardiography, Transesophageal | 3 | 2013 | 43 | 0.800 |
Why?
|
| ST Elevation Myocardial Infarction | 1 | 2023 | 34 | 0.800 |
Why?
|
| Enzymes | 2 | 2019 | 23 | 0.800 |
Why?
|
| Postoperative Complications | 3 | 2022 | 613 | 0.780 |
Why?
|
| Electric Stimulation Therapy | 3 | 2024 | 56 | 0.780 |
Why?
|
| Amyloid beta-Peptides | 1 | 2022 | 49 | 0.780 |
Why?
|
| Action Potentials | 5 | 2021 | 195 | 0.770 |
Why?
|
| Electric Countershock | 2 | 2024 | 29 | 0.760 |
Why?
|
| Time Factors | 12 | 2024 | 1593 | 0.740 |
Why?
|
| Hypertension | 3 | 2024 | 309 | 0.730 |
Why?
|
| Spironolactone | 1 | 2021 | 4 | 0.720 |
Why?
|
| Neuropeptide Y | 1 | 2020 | 3 | 0.700 |
Why?
|
| Prosencephalon | 1 | 2020 | 7 | 0.700 |
Why?
|
| Autonomic Pathways | 2 | 2018 | 16 | 0.700 |
Why?
|
| Mass Screening | 2 | 2022 | 152 | 0.700 |
Why?
|
| Brain Stem | 1 | 2020 | 23 | 0.690 |
Why?
|
| Lenses | 2 | 2018 | 12 | 0.690 |
Why?
|
| MicroRNAs | 1 | 2024 | 299 | 0.670 |
Why?
|
| Kidney | 3 | 2023 | 286 | 0.660 |
Why?
|
| Biocatalysis | 1 | 2019 | 22 | 0.660 |
Why?
|
| Pressoreceptors | 1 | 2019 | 8 | 0.660 |
Why?
|
| Bradycardia | 1 | 2020 | 17 | 0.650 |
Why?
|
| Magnetic Field Therapy | 1 | 2019 | 3 | 0.650 |
Why?
|
| Receptor, Muscarinic M2 | 2 | 2010 | 15 | 0.650 |
Why?
|
| Renal Artery | 1 | 2019 | 15 | 0.650 |
Why?
|
| Receptors, Adrenergic, beta-1 | 2 | 2010 | 22 | 0.650 |
Why?
|
| Enzyme Assays | 2 | 2019 | 6 | 0.640 |
Why?
|
| Sympathectomy | 1 | 2019 | 16 | 0.640 |
Why?
|
| Arrhythmogenic Right Ventricular Dysplasia | 1 | 2019 | 2 | 0.640 |
Why?
|
| Primary Health Care | 1 | 2021 | 152 | 0.640 |
Why?
|
| Optical Imaging | 2 | 2022 | 33 | 0.640 |
Why?
|
| Spinal Cord | 1 | 2021 | 209 | 0.640 |
Why?
|
| Ventricular Function, Right | 1 | 2019 | 13 | 0.640 |
Why?
|
| Kinetics | 8 | 2024 | 545 | 0.610 |
Why?
|
| Coronary Sinus | 1 | 2018 | 4 | 0.610 |
Why?
|
| Antioxidants | 1 | 2020 | 225 | 0.600 |
Why?
|
| Blood Vessel Prosthesis | 1 | 2018 | 28 | 0.600 |
Why?
|
| Rats | 4 | 2024 | 1568 | 0.600 |
Why?
|
| Tachycardia, Atrioventricular Nodal Reentry | 1 | 2018 | 29 | 0.600 |
Why?
|
| Earthquakes | 1 | 2018 | 5 | 0.590 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2018 | 36 | 0.590 |
Why?
|
| Ventricular Fibrillation | 2 | 2019 | 40 | 0.580 |
Why?
|
| Angina Pectoris | 1 | 2018 | 109 | 0.580 |
Why?
|
| Autonomic Denervation | 2 | 2021 | 19 | 0.560 |
Why?
|
| Endovascular Procedures | 1 | 2018 | 70 | 0.560 |
Why?
|
| Acute Coronary Syndrome | 1 | 2018 | 64 | 0.550 |
Why?
|
| Prevalence | 5 | 2021 | 494 | 0.550 |
Why?
|
| Hospitalization | 4 | 2023 | 202 | 0.540 |
Why?
|
| Cardiomyopathies | 1 | 2017 | 33 | 0.530 |
Why?
|
| Prospective Studies | 5 | 2021 | 1253 | 0.520 |
Why?
|
| Equipment Design | 5 | 2019 | 217 | 0.520 |
Why?
|
| Heart Diseases | 2 | 2023 | 70 | 0.510 |
Why?
|
| beta-Galactosidase | 2 | 2017 | 24 | 0.510 |
Why?
|
| Anticoagulants | 3 | 2022 | 294 | 0.510 |
Why?
|
| Skin | 1 | 2017 | 148 | 0.510 |
Why?
|
| Disease Models, Animal | 7 | 2025 | 1462 | 0.510 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2016 | 46 | 0.510 |
Why?
|
| Comorbidity | 5 | 2023 | 257 | 0.500 |
Why?
|
| Neuroimmunomodulation | 1 | 2015 | 5 | 0.480 |
Why?
|
| Fibrosis | 3 | 2025 | 134 | 0.470 |
Why?
|
| Electron Transport Complex IV | 6 | 2007 | 40 | 0.470 |
Why?
|
| Dogs | 9 | 2018 | 509 | 0.460 |
Why?
|
| Double-Blind Method | 3 | 2021 | 417 | 0.460 |
Why?
|
| No-Reflow Phenomenon | 2 | 2012 | 2 | 0.450 |
Why?
|
| Coronary Circulation | 2 | 2012 | 30 | 0.450 |
Why?
|
| Smartphone | 3 | 2023 | 63 | 0.450 |
Why?
|
| Heart Injuries | 1 | 2013 | 8 | 0.430 |
Why?
|
| Lab-On-A-Chip Devices | 5 | 2023 | 11 | 0.430 |
Why?
|
| Cryosurgery | 1 | 2013 | 19 | 0.430 |
Why?
|
| Pericardium | 1 | 2013 | 47 | 0.430 |
Why?
|
| Single-Cell Analysis | 3 | 2024 | 50 | 0.420 |
Why?
|
| Tachycardia | 1 | 2013 | 72 | 0.420 |
Why?
|
| Equipment Failure Analysis | 1 | 2013 | 37 | 0.420 |
Why?
|
| Neoplastic Cells, Circulating | 2 | 2024 | 25 | 0.410 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2013 | 11 | 0.410 |
Why?
|
| Adult | 12 | 2025 | 7764 | 0.410 |
Why?
|
| Transcriptome | 2 | 2025 | 214 | 0.410 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2022 | 248 | 0.400 |
Why?
|
| Phosphatidylinositol 3-Kinase | 1 | 2012 | 8 | 0.400 |
Why?
|
| Coronary Vessels | 1 | 2013 | 152 | 0.400 |
Why?
|
| Oklahoma | 5 | 2021 | 1005 | 0.400 |
Why?
|
| Chromogranin A | 1 | 2012 | 3 | 0.390 |
Why?
|
| Evidence-Based Medicine | 1 | 2013 | 145 | 0.390 |
Why?
|
| Endocardium | 1 | 2012 | 16 | 0.390 |
Why?
|
| Syncope, Vasovagal | 1 | 2012 | 5 | 0.390 |
Why?
|
| Tachycardia, Ventricular | 3 | 2019 | 60 | 0.390 |
Why?
|
| RNA | 2 | 2024 | 111 | 0.380 |
Why?
|
| Nitric Oxide | 1 | 2012 | 152 | 0.370 |
Why?
|
| Pulmonary Veins | 2 | 2014 | 108 | 0.370 |
Why?
|
| Platelet Aggregation Inhibitors | 2 | 2022 | 191 | 0.360 |
Why?
|
| Myocardial Reperfusion Injury | 1 | 2010 | 9 | 0.350 |
Why?
|
| Pulmonary Veno-Occlusive Disease | 1 | 2010 | 4 | 0.350 |
Why?
|
| Recurrence | 3 | 2024 | 323 | 0.350 |
Why?
|
| Peptide Fragments | 1 | 2012 | 202 | 0.350 |
Why?
|
| Cardiac Surgical Procedures | 2 | 2023 | 173 | 0.340 |
Why?
|
| Diabetes Complications | 1 | 2011 | 66 | 0.340 |
Why?
|
| Prognosis | 4 | 2021 | 803 | 0.340 |
Why?
|
| Electrophysiologic Techniques, Cardiac | 5 | 2019 | 96 | 0.330 |
Why?
|
| Sodium Chloride, Dietary | 2 | 2020 | 12 | 0.330 |
Why?
|
| Receptors, Adrenergic, beta-2 | 1 | 2010 | 23 | 0.330 |
Why?
|
| Graves Disease | 1 | 2009 | 8 | 0.330 |
Why?
|
| Aspirin | 1 | 2011 | 124 | 0.320 |
Why?
|
| Heme | 4 | 2007 | 90 | 0.310 |
Why?
|
| Myocardial Ischemia | 2 | 2022 | 73 | 0.310 |
Why?
|
| Receptors, Adrenergic, beta | 4 | 2025 | 24 | 0.310 |
Why?
|
| Coronary Angiography | 4 | 2013 | 150 | 0.300 |
Why?
|
| Recovery of Function | 2 | 2019 | 118 | 0.300 |
Why?
|
| Proteins | 2 | 2020 | 252 | 0.290 |
Why?
|
| Pilot Projects | 2 | 2022 | 434 | 0.280 |
Why?
|
| Atrial Remodeling | 2 | 2024 | 4 | 0.270 |
Why?
|
| Phenotype | 3 | 2024 | 679 | 0.260 |
Why?
|
| Cardiac Myosins | 2 | 2025 | 17 | 0.250 |
Why?
|
| Signal Transduction | 1 | 2012 | 1433 | 0.250 |
Why?
|
| Mobile Applications | 2 | 2017 | 61 | 0.240 |
Why?
|
| Thermodynamics | 2 | 2022 | 93 | 0.240 |
Why?
|
| Temperature | 3 | 2022 | 213 | 0.240 |
Why?
|
| Agrochemicals | 1 | 2025 | 4 | 0.240 |
Why?
|
| Receptors, CCR2 | 1 | 2025 | 15 | 0.240 |
Why?
|
| Surface Properties | 4 | 2020 | 134 | 0.240 |
Why?
|
| Adrenergic beta-Antagonists | 3 | 2024 | 66 | 0.240 |
Why?
|
| Body Mass Index | 3 | 2018 | 398 | 0.240 |
Why?
|
| Follow-Up Studies | 2 | 2021 | 1015 | 0.230 |
Why?
|
| Myocarditis | 1 | 2025 | 21 | 0.230 |
Why?
|
| Cellulose | 1 | 2024 | 24 | 0.220 |
Why?
|
| Reproducibility of Results | 4 | 2017 | 773 | 0.220 |
Why?
|
| CRISPR-Associated Proteins | 1 | 2024 | 6 | 0.220 |
Why?
|
| Oxidative Phosphorylation | 1 | 2024 | 27 | 0.220 |
Why?
|
| Phosphofructokinase-2 | 1 | 2024 | 11 | 0.220 |
Why?
|
| Myocytes, Cardiac | 1 | 2024 | 60 | 0.220 |
Why?
|
| Immunoglobulin G | 3 | 2011 | 270 | 0.220 |
Why?
|
| CRISPR-Cas Systems | 1 | 2024 | 47 | 0.220 |
Why?
|
| Escherichia coli | 2 | 2017 | 336 | 0.210 |
Why?
|
| Predictive Value of Tests | 5 | 2016 | 475 | 0.210 |
Why?
|
| Retrospective Studies | 5 | 2018 | 2557 | 0.210 |
Why?
|
| Carbon Monoxide | 2 | 2007 | 47 | 0.210 |
Why?
|
| Zebrafish | 1 | 2024 | 98 | 0.210 |
Why?
|
| Diagnostic Imaging | 1 | 2023 | 68 | 0.200 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2025 | 301 | 0.200 |
Why?
|
| Atrial Appendage | 1 | 2023 | 32 | 0.200 |
Why?
|
| Hospitals | 1 | 2023 | 81 | 0.200 |
Why?
|
| Protein Denaturation | 1 | 2022 | 28 | 0.200 |
Why?
|
| Genetic Testing | 1 | 2023 | 68 | 0.200 |
Why?
|
| Protein Folding | 1 | 2022 | 47 | 0.200 |
Why?
|
| Mutation | 2 | 2024 | 849 | 0.200 |
Why?
|
| Diatoms | 1 | 2022 | 9 | 0.200 |
Why?
|
| alpha7 Nicotinic Acetylcholine Receptor | 1 | 2022 | 3 | 0.200 |
Why?
|
| Postural Orthostatic Tachycardia Syndrome | 1 | 2022 | 9 | 0.200 |
Why?
|
| Particle Size | 3 | 2020 | 101 | 0.200 |
Why?
|
| Elasticity | 2 | 2024 | 52 | 0.200 |
Why?
|
| Global Health | 2 | 2019 | 51 | 0.190 |
Why?
|
| Cross-Over Studies | 2 | 2020 | 134 | 0.190 |
Why?
|
| Butterflies | 1 | 2022 | 4 | 0.190 |
Why?
|
| Monocytes | 1 | 2023 | 135 | 0.190 |
Why?
|
| Cardiac Pacing, Artificial | 2 | 2012 | 146 | 0.190 |
Why?
|
| Gene Expression Profiling | 1 | 2024 | 451 | 0.190 |
Why?
|
| Fluorescence | 2 | 2018 | 49 | 0.190 |
Why?
|
| Spectrum Analysis | 2 | 2021 | 29 | 0.180 |
Why?
|
| Neuroglia | 1 | 2021 | 30 | 0.180 |
Why?
|
| Polymers | 1 | 2022 | 117 | 0.180 |
Why?
|
| Neurotransmitter Agents | 1 | 2021 | 21 | 0.180 |
Why?
|
| Purkinje Fibers | 3 | 2010 | 37 | 0.180 |
Why?
|
| Angioplasty, Balloon, Coronary | 2 | 2012 | 52 | 0.180 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2022 | 126 | 0.180 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2012 | 608 | 0.180 |
Why?
|
| Diuretics | 1 | 2021 | 12 | 0.180 |
Why?
|
| Caenorhabditis elegans | 1 | 2021 | 58 | 0.180 |
Why?
|
| Odds Ratio | 3 | 2017 | 237 | 0.180 |
Why?
|
| Caenorhabditis elegans Proteins | 1 | 2021 | 55 | 0.180 |
Why?
|
| Nanostructures | 1 | 2022 | 64 | 0.180 |
Why?
|
| Blood Flow Velocity | 2 | 2011 | 64 | 0.180 |
Why?
|
| Mice | 3 | 2025 | 4655 | 0.180 |
Why?
|
| Microdissection | 1 | 2020 | 15 | 0.170 |
Why?
|
| Organelles | 1 | 2020 | 6 | 0.170 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2024 | 330 | 0.170 |
Why?
|
| Optical Devices | 1 | 2020 | 3 | 0.170 |
Why?
|
| Leukemia | 1 | 2020 | 30 | 0.170 |
Why?
|
| Dementia | 1 | 2022 | 95 | 0.170 |
Why?
|
| Mice, Inbred C57BL | 1 | 2025 | 1573 | 0.170 |
Why?
|
| Surveys and Questionnaires | 1 | 2024 | 969 | 0.170 |
Why?
|
| Ear, External | 1 | 2020 | 13 | 0.170 |
Why?
|
| Bacteriophage lambda | 1 | 2019 | 3 | 0.170 |
Why?
|
| Brugada Syndrome | 1 | 2019 | 4 | 0.160 |
Why?
|
| Baroreflex | 1 | 2019 | 6 | 0.160 |
Why?
|
| Young Adult | 3 | 2018 | 2737 | 0.160 |
Why?
|
| Sex Characteristics | 1 | 2021 | 172 | 0.160 |
Why?
|
| Seizures | 1 | 2020 | 48 | 0.160 |
Why?
|
| DNA, Viral | 1 | 2019 | 55 | 0.160 |
Why?
|
| Adolescent | 3 | 2018 | 3126 | 0.160 |
Why?
|
| Chi-Square Distribution | 2 | 2017 | 145 | 0.160 |
Why?
|
| Metal Nanoparticles | 1 | 2021 | 130 | 0.160 |
Why?
|
| Survival Rate | 3 | 2019 | 430 | 0.150 |
Why?
|
| Secondary Prevention | 1 | 2019 | 47 | 0.150 |
Why?
|
| Diastole | 1 | 2018 | 22 | 0.150 |
Why?
|
| Jurkat Cells | 1 | 2018 | 30 | 0.150 |
Why?
|
| Diet | 1 | 2020 | 232 | 0.150 |
Why?
|
| Infant | 1 | 2022 | 1010 | 0.150 |
Why?
|
| Neurons | 1 | 2020 | 282 | 0.150 |
Why?
|
| Sex Factors | 2 | 2018 | 465 | 0.150 |
Why?
|
| Tuberculosis | 1 | 2018 | 25 | 0.150 |
Why?
|
| Disasters | 1 | 2018 | 16 | 0.150 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2018 | 31 | 0.150 |
Why?
|
| Methylamines | 1 | 2018 | 6 | 0.150 |
Why?
|
| Saliva | 1 | 2018 | 96 | 0.150 |
Why?
|
| Biomechanical Phenomena | 1 | 2018 | 180 | 0.140 |
Why?
|
| Oxidants | 1 | 2018 | 31 | 0.140 |
Why?
|
| Algorithms | 4 | 2023 | 433 | 0.140 |
Why?
|
| Cytological Techniques | 1 | 2017 | 6 | 0.140 |
Why?
|
| Heart Conduction System | 3 | 2014 | 270 | 0.140 |
Why?
|
| Postoperative Period | 1 | 2017 | 67 | 0.140 |
Why?
|
| Thoracic Surgery | 1 | 2017 | 14 | 0.140 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2018 | 544 | 0.140 |
Why?
|
| DNA, Bacterial | 1 | 2018 | 306 | 0.130 |
Why?
|
| Electrocardiography, Ambulatory | 1 | 2017 | 14 | 0.130 |
Why?
|
| Viscosity | 3 | 2024 | 38 | 0.130 |
Why?
|
| Prosthesis Design | 1 | 2017 | 87 | 0.130 |
Why?
|
| Polyethylene Glycols | 1 | 2017 | 101 | 0.130 |
Why?
|
| United States | 2 | 2021 | 2150 | 0.130 |
Why?
|
| Phenethylamines | 1 | 2016 | 5 | 0.130 |
Why?
|
| Patient Selection | 1 | 2017 | 148 | 0.130 |
Why?
|
| Sotalol | 1 | 2016 | 9 | 0.130 |
Why?
|
| Drug Administration Schedule | 1 | 2016 | 224 | 0.130 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2018 | 123 | 0.130 |
Why?
|
| Disease Progression | 1 | 2018 | 474 | 0.130 |
Why?
|
| Ovarian Neoplasms | 1 | 2022 | 595 | 0.130 |
Why?
|
| Inpatients | 1 | 2016 | 56 | 0.120 |
Why?
|
| Interleukin-6 | 1 | 2017 | 194 | 0.120 |
Why?
|
| Sulfonamides | 1 | 2016 | 73 | 0.120 |
Why?
|
| Hemorrhage | 2 | 2022 | 265 | 0.120 |
Why?
|
| Acetylcholine | 2 | 2012 | 73 | 0.120 |
Why?
|
| Copper | 2 | 2007 | 47 | 0.120 |
Why?
|
| Case-Control Studies | 3 | 2016 | 724 | 0.120 |
Why?
|
| Lasers | 1 | 2015 | 67 | 0.120 |
Why?
|
| Electromagnetic Fields | 1 | 2014 | 14 | 0.120 |
Why?
|
| Age Factors | 1 | 2017 | 733 | 0.120 |
Why?
|
| Cytochrome b Group | 3 | 2004 | 6 | 0.120 |
Why?
|
| C-Reactive Protein | 1 | 2015 | 92 | 0.110 |
Why?
|
| Enzyme Activation | 1 | 2015 | 267 | 0.110 |
Why?
|
| Diagnosis, Differential | 2 | 2013 | 372 | 0.110 |
Why?
|
| Foreign-Body Migration | 1 | 2014 | 8 | 0.110 |
Why?
|
| Electrodes, Implanted | 1 | 2014 | 40 | 0.110 |
Why?
|
| Prosthesis-Related Infections | 1 | 2014 | 14 | 0.110 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2014 | 41 | 0.110 |
Why?
|
| Device Removal | 1 | 2014 | 30 | 0.110 |
Why?
|
| Cohort Studies | 2 | 2016 | 889 | 0.110 |
Why?
|
| Sertraline | 1 | 2013 | 5 | 0.110 |
Why?
|
| Serotonin Uptake Inhibitors | 1 | 2013 | 26 | 0.110 |
Why?
|
| Hydralazine | 1 | 2013 | 6 | 0.110 |
Why?
|
| Atrial Flutter | 1 | 2013 | 13 | 0.110 |
Why?
|
| Ultrasonography | 2 | 2014 | 241 | 0.110 |
Why?
|
| Isosorbide Dinitrate | 1 | 2013 | 24 | 0.110 |
Why?
|
| Atropine | 2 | 2012 | 47 | 0.100 |
Why?
|
| Spectroscopy, Fourier Transform Infrared | 5 | 2007 | 36 | 0.100 |
Why?
|
| Oxygen | 3 | 2004 | 234 | 0.100 |
Why?
|
| Vasodilator Agents | 1 | 2013 | 79 | 0.100 |
Why?
|
| Pulmonary Embolism | 1 | 2014 | 126 | 0.100 |
Why?
|
| Aged, 80 and over | 3 | 2013 | 2021 | 0.100 |
Why?
|
| Sick Sinus Syndrome | 1 | 2012 | 5 | 0.100 |
Why?
|
| Myocardial Contraction | 2 | 2009 | 62 | 0.100 |
Why?
|
| Refractory Period, Electrophysiological | 1 | 2012 | 21 | 0.100 |
Why?
|
| Healthcare Disparities | 1 | 2013 | 92 | 0.100 |
Why?
|
| Brain Ischemia | 1 | 2013 | 85 | 0.100 |
Why?
|
| Embolic Protection Devices | 1 | 2012 | 7 | 0.090 |
Why?
|
| Receptors, Muscarinic | 1 | 2011 | 9 | 0.090 |
Why?
|
| Saphenous Vein | 1 | 2012 | 24 | 0.090 |
Why?
|
| Graft Occlusion, Vascular | 1 | 2012 | 22 | 0.090 |
Why?
|
| Hypotension, Orthostatic | 1 | 2011 | 8 | 0.090 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2013 | 163 | 0.090 |
Why?
|
| Sensitivity and Specificity | 1 | 2013 | 521 | 0.090 |
Why?
|
| Thrombosis | 1 | 2013 | 149 | 0.090 |
Why?
|
| Glomerulonephritis, Membranous | 1 | 2011 | 2 | 0.090 |
Why?
|
| Logistic Models | 4 | 2013 | 407 | 0.090 |
Why?
|
| Exercise Test | 1 | 2012 | 248 | 0.090 |
Why?
|
| Nerve Net | 1 | 2012 | 106 | 0.090 |
Why?
|
| African Americans | 1 | 2013 | 350 | 0.090 |
Why?
|
| Photons | 2 | 2022 | 27 | 0.090 |
Why?
|
| Atrial Function, Left | 1 | 2010 | 4 | 0.090 |
Why?
|
| Reoperation | 1 | 2011 | 145 | 0.090 |
Why?
|
| Laser-Doppler Flowmetry | 1 | 2010 | 16 | 0.090 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2011 | 75 | 0.090 |
Why?
|
| Contrast Media | 1 | 2011 | 97 | 0.090 |
Why?
|
| Microchemistry | 1 | 2009 | 3 | 0.080 |
Why?
|
| Adrenergic beta-Agonists | 1 | 2010 | 19 | 0.080 |
Why?
|
| Swine | 1 | 2010 | 237 | 0.080 |
Why?
|
| Cell Line, Tumor | 2 | 2024 | 1327 | 0.080 |
Why?
|
| Cricetinae | 1 | 2009 | 130 | 0.080 |
Why?
|
| Blood Pressure | 1 | 2010 | 355 | 0.080 |
Why?
|
| Fluorescent Dyes | 1 | 2009 | 90 | 0.080 |
Why?
|
| Coronary Artery Disease | 1 | 2012 | 217 | 0.080 |
Why?
|
| Solutions | 2 | 2020 | 31 | 0.080 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2016 | 991 | 0.080 |
Why?
|
| Cell Line | 2 | 2021 | 694 | 0.080 |
Why?
|
| Limit of Detection | 2 | 2018 | 25 | 0.070 |
Why?
|
| HL-60 Cells | 2 | 2017 | 22 | 0.070 |
Why?
|
| Nickel | 1 | 2007 | 15 | 0.070 |
Why?
|
| Thermus thermophilus | 2 | 2004 | 7 | 0.070 |
Why?
|
| Autoimmune Diseases | 1 | 2007 | 164 | 0.060 |
Why?
|
| Microscopy, Fluorescence | 2 | 2021 | 163 | 0.060 |
Why?
|
| Neurosciences | 1 | 2025 | 10 | 0.060 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 2025 | 19 | 0.060 |
Why?
|
| Cross Reactions | 1 | 2025 | 72 | 0.060 |
Why?
|
| Liquid Biopsy | 1 | 2024 | 9 | 0.060 |
Why?
|
| Organogenesis | 1 | 2004 | 12 | 0.060 |
Why?
|
| Diffusion | 1 | 2024 | 39 | 0.060 |
Why?
|
| Emulsions | 1 | 2024 | 25 | 0.060 |
Why?
|
| Nerve Fibers | 1 | 2004 | 53 | 0.060 |
Why?
|
| Acetobacteraceae | 1 | 2024 | 2 | 0.060 |
Why?
|
| Afferent Pathways | 1 | 2004 | 62 | 0.060 |
Why?
|
| Replication Protein A | 1 | 2024 | 1 | 0.060 |
Why?
|
| Fetal Development | 1 | 2004 | 25 | 0.060 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2024 | 7 | 0.060 |
Why?
|
| Endodeoxyribonucleases | 1 | 2024 | 7 | 0.060 |
Why?
|
| Pyruvates | 1 | 2024 | 11 | 0.060 |
Why?
|
| Models, Animal | 2 | 2014 | 128 | 0.060 |
Why?
|
| Epitopes | 1 | 2025 | 179 | 0.060 |
Why?
|
| Mutation, Missense | 1 | 2024 | 69 | 0.050 |
Why?
|
| Biopsy | 1 | 2024 | 207 | 0.050 |
Why?
|
| Biosensing Techniques | 1 | 2024 | 43 | 0.050 |
Why?
|
| Biological Specimen Banks | 1 | 2023 | 10 | 0.050 |
Why?
|
| Colchicine | 1 | 2023 | 16 | 0.050 |
Why?
|
| CX3C Chemokine Receptor 1 | 1 | 2023 | 7 | 0.050 |
Why?
|
| Receptors, Chemokine | 1 | 2023 | 11 | 0.050 |
Why?
|
| United Kingdom | 1 | 2023 | 75 | 0.050 |
Why?
|
| Aftercare | 1 | 2023 | 33 | 0.050 |
Why?
|
| Bone Marrow Transplantation | 1 | 2023 | 49 | 0.050 |
Why?
|
| Tachycardia, Sinus | 1 | 2022 | 8 | 0.050 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2023 | 69 | 0.050 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2023 | 180 | 0.050 |
Why?
|
| Antigen-Antibody Reactions | 1 | 2022 | 12 | 0.050 |
Why?
|
| Pseudomonas | 1 | 2002 | 13 | 0.050 |
Why?
|
| Metabolome | 1 | 2023 | 68 | 0.050 |
Why?
|
| Blood Glucose | 1 | 2024 | 311 | 0.050 |
Why?
|
| Vitamin K | 1 | 2022 | 39 | 0.050 |
Why?
|
| Ferrous Compounds | 1 | 2002 | 17 | 0.050 |
Why?
|
| Exosomes | 1 | 2024 | 91 | 0.050 |
Why?
|
| Cell Separation | 1 | 2022 | 55 | 0.050 |
Why?
|
| Glucose | 1 | 2024 | 203 | 0.050 |
Why?
|
| Patient Discharge | 1 | 2023 | 103 | 0.050 |
Why?
|
| Proteomics | 1 | 2024 | 181 | 0.050 |
Why?
|
| Insulin | 1 | 2024 | 315 | 0.050 |
Why?
|
| Nitroso Compounds | 1 | 2002 | 23 | 0.050 |
Why?
|
| Metabolomics | 1 | 2023 | 85 | 0.050 |
Why?
|
| Autonomic Nerve Block | 1 | 2022 | 3 | 0.050 |
Why?
|
| Fibrinolytic Agents | 1 | 2022 | 70 | 0.050 |
Why?
|
| Administration, Oral | 1 | 2022 | 190 | 0.050 |
Why?
|
| Length of Stay | 1 | 2023 | 232 | 0.050 |
Why?
|
| Multivariate Analysis | 2 | 2013 | 300 | 0.050 |
Why?
|
| Color | 1 | 2022 | 23 | 0.050 |
Why?
|
| Antibodies | 1 | 2022 | 124 | 0.050 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2024 | 555 | 0.050 |
Why?
|
| Heat-Shock Response | 1 | 2021 | 13 | 0.050 |
Why?
|
| Proteostasis | 1 | 2021 | 9 | 0.050 |
Why?
|
| Fluorescein | 1 | 2021 | 6 | 0.050 |
Why?
|
| Proof of Concept Study | 1 | 2021 | 12 | 0.050 |
Why?
|
| Carbon | 1 | 2002 | 108 | 0.050 |
Why?
|
| Spinal Cord Stimulation | 1 | 2021 | 13 | 0.050 |
Why?
|
| Light | 1 | 2022 | 118 | 0.050 |
Why?
|
| Luminescent Proteins | 1 | 2021 | 25 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2024 | 677 | 0.040 |
Why?
|
| Iron | 1 | 2002 | 116 | 0.040 |
Why?
|
| Phase Transition | 1 | 2020 | 3 | 0.040 |
Why?
|
| Bacterial Proteins | 1 | 2024 | 485 | 0.040 |
Why?
|
| Syncope | 1 | 2019 | 10 | 0.040 |
Why?
|
| Gold | 1 | 2021 | 130 | 0.040 |
Why?
|
| Medical History Taking | 1 | 2019 | 18 | 0.040 |
Why?
|
| Machine Learning | 1 | 2021 | 85 | 0.040 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2021 | 174 | 0.040 |
Why?
|
| Cause of Death | 1 | 2019 | 73 | 0.040 |
Why?
|
| Point-of-Care Systems | 1 | 2018 | 21 | 0.040 |
Why?
|
| Colorimetry | 1 | 2017 | 15 | 0.040 |
Why?
|
| Random Allocation | 1 | 2018 | 151 | 0.040 |
Why?
|
| Cross-Sectional Studies | 1 | 2021 | 969 | 0.040 |
Why?
|
| Linear Models | 1 | 2017 | 203 | 0.030 |
Why?
|
| Inflammation Mediators | 1 | 2018 | 165 | 0.030 |
Why?
|
| Water | 2 | 2009 | 135 | 0.030 |
Why?
|
| Pseudomonas stutzeri | 2 | 2007 | 2 | 0.030 |
Why?
|
| Healthy Volunteers | 1 | 2016 | 50 | 0.030 |
Why?
|
| Neoplasms | 1 | 2024 | 818 | 0.030 |
Why?
|
| Models, Chemical | 2 | 2007 | 90 | 0.030 |
Why?
|
| Binding Sites | 2 | 2007 | 354 | 0.030 |
Why?
|
| Rabbits | 1 | 2014 | 276 | 0.030 |
Why?
|
| Models, Molecular | 2 | 2007 | 453 | 0.030 |
Why?
|
| Drug Utilization Review | 1 | 2013 | 7 | 0.030 |
Why?
|
| Drug Combinations | 1 | 2013 | 50 | 0.030 |
Why?
|
| Guideline Adherence | 1 | 2013 | 95 | 0.020 |
Why?
|
| Exercise | 1 | 2017 | 482 | 0.020 |
Why?
|
| Hydrogen-Ion Concentration | 2 | 2003 | 267 | 0.020 |
Why?
|
| Depressive Disorder, Major | 1 | 2013 | 127 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2013 | 242 | 0.020 |
Why?
|
| Posture | 1 | 2011 | 39 | 0.020 |
Why?
|
| Electric Stimulation | 1 | 2012 | 255 | 0.020 |
Why?
|
| Cattle | 2 | 2004 | 389 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2012 | 112 | 0.020 |
Why?
|
| Cardiac Catheterization | 1 | 2012 | 113 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2012 | 390 | 0.020 |
Why?
|
| Registries | 1 | 2013 | 386 | 0.020 |
Why?
|
| Hospital Mortality | 1 | 2012 | 149 | 0.020 |
Why?
|
| Veterans | 1 | 2012 | 69 | 0.020 |
Why?
|
| Vasodilation | 1 | 2011 | 114 | 0.020 |
Why?
|
| Lipids | 1 | 2012 | 208 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2012 | 454 | 0.020 |
Why?
|
| Colloids | 1 | 2009 | 9 | 0.020 |
Why?
|
| Fluorescence Resonance Energy Transfer | 1 | 2009 | 18 | 0.020 |
Why?
|
| Spectrometry, Fluorescence | 1 | 2009 | 64 | 0.020 |
Why?
|
| Microspheres | 1 | 2009 | 49 | 0.020 |
Why?
|
| Nanotechnology | 1 | 2009 | 68 | 0.020 |
Why?
|
| Hot Temperature | 1 | 2009 | 87 | 0.020 |
Why?
|
| Pheochromocytoma | 1 | 2007 | 9 | 0.020 |
Why?
|
| Photolysis | 1 | 2007 | 4 | 0.020 |
Why?
|
| Organ Culture Techniques | 1 | 2007 | 56 | 0.020 |
Why?
|
| Biological Assay | 1 | 2007 | 35 | 0.020 |
Why?
|
| Syndrome | 1 | 2007 | 78 | 0.020 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2007 | 33 | 0.020 |
Why?
|
| Antihypertensive Agents | 1 | 2007 | 56 | 0.020 |
Why?
|
| Reference Values | 1 | 2007 | 200 | 0.020 |
Why?
|
| Antibody Specificity | 1 | 2007 | 114 | 0.020 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2007 | 123 | 0.020 |
Why?
|
| Proton-Motive Force | 1 | 2004 | 1 | 0.010 |
Why?
|
| Cytochromes a | 1 | 2004 | 1 | 0.010 |
Why?
|
| Cytochromes a3 | 1 | 2004 | 1 | 0.010 |
Why?
|
| Cytochrome c Group | 1 | 2004 | 10 | 0.010 |
Why?
|
| In Vitro Techniques | 1 | 2004 | 242 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2004 | 463 | 0.010 |
Why?
|
| Spectrum Analysis, Raman | 1 | 2002 | 32 | 0.010 |
Why?
|
| Ligands | 1 | 2003 | 176 | 0.010 |
Why?
|
| Spectrophotometry | 1 | 2002 | 34 | 0.010 |
Why?
|
| Protons | 1 | 2002 | 54 | 0.010 |
Why?
|
| Oxidation-Reduction | 1 | 2003 | 363 | 0.010 |
Why?
|
| Cell Nucleus | 1 | 2002 | 138 | 0.010 |
Why?
|